Ingevity
NGVTNYSEUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $63.24 Prior regular-session close from the quote source.
- $61.92–$63.44 Regular-session low and high so far today.
- 283.3K Regular-session shares traded · Nov 12, 4:00 PM ET.
- Feb 24 projected Projected for 2027-02-24 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
- $46.38–$79.29 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own NGVT if Ingevity can become a higher‑margin, cash‑generative specialty materials company by exiting cyclical, low‑margin industrial businesses, focusing on Performance Materials and Pavement Technologies, and converting realized cost and footprint savings into durable operating profit and.
NGVT price history
Loading recent earnings…
Investment thesis
What must happen next
Removing low‑margin, cyclical industrial specialties and capturing repositioning savings will sustain operating income and margins despite a smaller revenue base because the remaining businesses are higher‑value, mission‑critical products with pricing and margin resilience.StrengtheningMateriality: High
OperatingIncomeLoss remained roughly stable at $452,600,000 (2022) → $423,200,000 (2023) → $425,900,000 (2024) → $418,700,000 (2025) even as revenue fell. If true, shareholders get durable operating profit and cash generation from a simpler portfolio; if false, profit will drift lower and the stock needs re‑rating downward or more capital actions.
Watch: Failure to monetize remaining APT/pavement asset sales or need to retain low‑margin operations rather than sell.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
OperatingIncomeLoss remained roughly stable at $452,600,000 (2022) → $423,200,000 (2023) → $425,900,000 (2024) → $418,700,000 (2025) even as revenue fell.
Open source ↗Demand for mission‑critical products (automotive vapor control, filtration, pavement materials) plus operational savings will convert into stable operating cash flow, making earnings less sensitive to revenue cyclicality.HoldingMateriality: High
NetCashProvidedByUsedInOperatingActivities: $313,400,000 (2022) → $205,100,000 (2023) → $128,600,000 (2024) → $331,200,000 (2025), showing a strong rebound in 2025. Sustained operating cash flow backs a higher multiple and funds buybacks/debt paydown; if cash flow is volatile, the company may need to access capital or sell assets.
Watch: A macro downturn that reduces automotive or infrastructure activity materially (less traffic/infrastructure spend), lowering volumes in core end markets.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
NetCashProvidedByUsedInOperatingActivities: $313,400,000 (2022) → $205,100,000 (2023) → $128,600,000 (2024) → $331,200,000 (2025), showing a strong rebound in 2025.
Open source ↗Reported earnings will remain volatile until remaining strategic actions complete because prior impairments (e.g., road markings) show asset valuations are uncertain and sales processes can trigger additional write‑downs.StrengtheningMateriality: Medium
NetIncomeLoss swung from $211,600,000 (2022) to negative results: $(5,400,000) (2023), $(430,300,000) (2024), $(167,100,000) (2025). If further impairments occur, book equity and investor returns will be damaged even if underlying operations are solid; avoiding new impairments is necessary for valuation recovery.
Watch: Failure to complete sales of APT or remaining Performance Chemicals lines, forcing management to retain underperforming assets.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
NetIncomeLoss swung from $211,600,000 (2022) to negative results: $(5,400,000) (2023), $(430,300,000) (2024), $(167,100,000) (2025).
Open source ↗The balance sheet is fragile (very low reported equity), so management must either restore equity via earnings/cash flow or execute asset sales; otherwise the company risks forced capital actions or dilution.StrengtheningMateriality: Medium
StockholdersEquity declined from $698,300,000 (2022) to $195,200,000 (2024) and to $29,700,000 (2025). Low equity increases the risk that an adverse event (another large impairment, covenant breach) forces fire sales or dilution that destroys expected returns.
Watch: Inability to refinance or access capital markets on acceptable terms if needed (market disruption).
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
StockholdersEquity declined from $698,300,000 (2022) to $195,200,000 (2024) and to $29,700,000 (2025).
Open source ↗The current market valuation implies management will avoid further material impairments and will convert the repositioning savings into recurring operating income; to justify the stock, operating income and cash flow must remain near or above recent pre‑restructuring levels.HoldingMateriality: Medium
OperatingIncomeLoss has been around $420–$452 million across 2022–2025 despite revenue declines. If management misses those execution milestones, the market will re‑rate the company downward even if top‑line recovery is slow.
Watch: A new large impairment or restructuring charge that cuts operating income materially (e.g., another asset group impairment).
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
OperatingIncomeLoss has been around $420–$452 million across 2022–2025 despite revenue declines.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Removing low‑margin, cyclical industrial specialties and capturing repositioning savings will sustain operating income and margins despite a smaller revenue base because the remaining businesses are higher‑value, mission‑critical products with pricing and margin resilience. If true, shareholders get durable operating profit and cash generation from a simpler portfolio; if false, profit will drift lower and the stock needs re‑rating downward or more capital actions.
Demand for mission‑critical products (automotive vapor control, filtration, pavement materials) plus operational savings will convert into stable operating cash flow, making earnings less sensitive to revenue cyclicality. Sustained operating cash flow backs a higher multiple and funds buybacks/debt paydown; if cash flow is volatile, the company may need to access capital or sell assets.
Reported earnings will remain volatile until remaining strategic actions complete because prior impairments (e.g., road markings) show asset valuations are uncertain and sales processes can trigger additional write‑downs. If further impairments occur, book equity and investor returns will be damaged even if underlying operations are solid; avoiding new impairments is necessary for valuation recovery.
The balance sheet is fragile (very low reported equity), so management must either restore equity via earnings/cash flow or execute asset sales; otherwise the company risks forced capital actions or dilution. Low equity increases the risk that an adverse event (another large impairment, covenant breach) forces fire sales or dilution that destroys expected returns.
The current market valuation implies management will avoid further material impairments and will convert the repositioning savings into recurring operating income; to justify the stock, operating income and cash flow must remain near or above recent pre‑restructuring levels. If management misses those execution milestones, the market will re‑rate the company downward even if top‑line recovery is slow.
All standing thesis claims
Original report summary
Ingevity can become a higher‑margin, cash‑generative specialty materials company by exiting cyclical, low‑margin industrial businesses, focusing on Performance Materials and Pavement Technologies, and converting realized cost and footprint savings into durable operating profit and.
Bull case and bear case
Bull case and bear case for Ingevity
Where the evidence on Ingevity stands: Holding on the latest evidence (Nov 12, 2026). Of its 5 thesis points, 3 strengthening and 2 holding.
Bull case: what the evidence supports
Removing low‑margin, cyclical industrial specialties and capturing repositioning savings will sustain operating income and margins despite a smaller revenue base because the remaining businesses are higher‑value, mission‑critical products with pricing and margin resilience.
Demand for mission‑critical products (automotive vapor control, filtration, pavement materials) plus operational savings will convert into stable operating cash flow, making earnings less sensitive to revenue cyclicality.
Reported earnings will remain volatile until remaining strategic actions complete because prior impairments (e.g., road markings) show asset valuations are uncertain and sales processes can trigger additional write‑downs.
The balance sheet is fragile (very low reported equity), so management must either restore equity via earnings/cash flow or execute asset sales; otherwise the company risks forced capital actions or dilution.
The current market valuation implies management will avoid further material impairments and will convert the repositioning savings into recurring operating income; to justify the stock, operating income and cash flow must remain near or above recent pre‑restructuring levels.
Bear case: what would count against it
Failure to monetize remaining APT/pavement asset sales or need to retain low‑margin operations rather than sell.
A macro downturn that reduces automotive or infrastructure activity materially (less traffic/infrastructure spend), lowering volumes in core end markets.
Failure to complete sales of APT or remaining Performance Chemicals lines, forcing management to retain underperforming assets.
Thesis-Break Engine
Thesis-break watch · Ingevity
No break has crossed Ingevity’s thesis. Its break conditions are checked against every new filing as it lands.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedReported results of operations (earnings release).
Ingevity filed an SEC 8-K on 2026-11-04: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
Ingevity filed an SEC 8-K on 2026-07-29: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedDirector or principal officer change.
Ingevity filed an SEC 8-K on 2026-06-24: Director or principal officer change. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Failure to monetize remaining APT/pavement asset sales or need to retain low‑margin operations rather than sell.
- A macro downturn that reduces automotive or infrastructure activity materially (less traffic/infrastructure spend), lowering volumes in core end markets.
- Failure to complete sales of APT or remaining Performance Chemicals lines, forcing management to retain underperforming assets.
- Inability to refinance or access capital markets on acceptable terms if needed (market disruption).
- A new large impairment or restructuring charge that cuts operating income materially (e.g., another asset group impairment).
NGVT news
Loading headlines…
Financial statements
NGVT income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
NGVT: quick answers
- When does Ingevity (NGVT) report earnings next?
- Ingevity's next results are projected for February 24, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 4, 2026. Earnings calendar
- What is NGVT's short interest?
- As of October 30, 2026, 1.3M NGVT shares were sold short, 3.71% of its shares outstanding, down 8.2% from the count before. At the stock's average daily volume that is 4.4 days to cover. FINRA publishes the count twice a month. NGVT short interest history
- Have members of Congress traded NGVT?
- 1 trade in NGVT has been disclosed under the STOCK Act by members of Congress, the President or senior officials, none in reports made public in the last 90 days. Every disclosed NGVT trade
- Which well-known investors own NGVT?
- 1 of the 37 well-known funds tracked here reported NGVT shares in their latest 13F filing. By share of the fund's portfolio: Bridgewater Associates (Ray Dalio), 0.0%. Fund portfolios
NGVT in well-known investors’ portfolios
1 of 37 funds reported NGVT shares in their latest 13F filing. A 13F shows quarter-end positions and arrives up to 45 days later.
| Fund | Of its portfolio | Value | Change | Quarter |
|---|---|---|---|---|
| Ray DalioBridgewater Associates | 0.01% | $1.6M | +19.8% | Q2 2026 |
